€0.31
Your prediction
Financial data and news for Recce Pharmaceuticals Ltd.
sharewise wants to provide you with the best news and tools for Recce Pharmaceuticals Ltd., so we directly link to the best financial data sources.
Financials
News
U.S. Department of Defense Grants US$2 million for RECCE® 327 Gel
Highlights:
- US Department of Defense grants funding of US$2 million (approximately A$3 million)
- Funding to accelerate development of RECCE® 327 Gel (R327G) for
Positive Efficacy Data from Murdoch Children’s Research Institute in Study against WHO Priority Pathogen Acinetobacter baumannii
Highlights:
- RECCE® 327 (R327) demonstrates significant bactericidal activity against ‘superbug’ Acinetobacter baumannii (A. baumannii) in adult human epidermal ‘skin’ cells:
Recce Pharmaceuticals Reports Positive Data From Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial of RECCE® 327
Highlights:
- Phase I/II rapid infusion clinical trial demonstrates efficacy on bacterial growth in dosed participants injected with RECCE® 327 (R327) at the highest tested dose of
RECCE® 327 added to The World Health Organization’s List of Antibacterial Products in Clinical Development
Highlights:
- Global recognition by the World Health Organization (WHO) – inclusion underscores significance of RECCE® 327 (R327) in combating antimicrobial resistance
-
Positive Efficacy Data from Murdoch Children’s Research Institute in Pilot Study for Lung Infections
Highlights:
- RECCE® 327 (R327) demonstrates efficacy in treating Mycobacterium abscessus lung infections using recently developed nebuliser delivery method: >99% log reduction
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
- Recce recognized by the United Kingdom Government Innovation Agency among the most promising organizations for the UK AMR Inward Mission 2024.
- Recce chosen as one of 18
Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) Business Update
Highlights:
- Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II UTI/Urosepsis Trial with an increase in dosage expected to begin in the next several weeks
-
Successful Completion of Share Purchase Plan
Highlights:
- Share Purchase Plan receives A$4.4 million of valid applications
- Total funds raised of A$12.4 million, in conjunction with recently completed A$8.0
Recce Pharmaceuticals Receives Ethics Approval to Centralise and Broaden RECCE® 327 Gel Clinical Trials across all Topical Bacterial Skin Infections
Highlights:
- Positions RECCE® 327 (R327) Gel as potential broad application topical therapeutic for all bacterial skin infections, formally referred to as complicated skin and
Further R&D Rebate Approved
SYDNEY Australia, 18 June 2024: Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of Synthetic Anti-infectives, is pleased to announce a
Cohort Dosing Complete – Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
Highlights:
- Dosing of 6 human subjects complete in Phase I/II UTI/Urosepsis fast infusion intravenous study of RECCE® 327 (R327) at 4,000mg over 20 minutes – highest dosage to
First Participants Dosed in Next Cohort - Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
Highlights:
- First participants (male/female) successfully dosed at 4,000mg (I.V.), over 20 minutes, 4,000mg highest dosage to date in this clinical trial
- RECCE® 327
Recce Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
Highlights:
- Successful production of 5,000 x RECCE® 327 (R327) doses per week under Good Manufacturing Practises (GMP) campaign.
- R327 manufactured under GMP